Extended Rosiglitazone (RSG XR) compared to placebo and moxifloxacin

• Research type

  Research Study

• Full title

  A study to evaluate the effect of extended release Rosiglitazone (RSG XR) on cardiac conduction as compared to placebo and a single oral dose of moxifloxacin.

• IRAS ID

  12371

• Sponsor organisation

  GlaxoSmithKline Research & Development Limited

• Eudract number

  2008-006204-38

• ISRCTN Number

  No number provided

• Clinicaltrials.gov Identifier

  No number provided

• Research summary

  Research Summary not published at request of researcher

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  08/H0804/161

• Date of REC Opinion

  8 Apr 2009

• REC opinion

  Further Information Favourable Opinion